Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
30 Autism Trials near Albuquerque, NM
Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerCM-AT for Autism
Albuquerque, New Mexico
This trial is testing a special enzyme powder called CM-AT to help children with autism digest protein better.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3 - 17
Key Eligibility Criteria
Disqualifiers:Seizures, Severe Trauma, Systemic Disease, Others
Must Not Be Taking:Stimulants, Non-stimulants, ADHD Meds
405 Participants Needed
tDCS + Social Learning for Autism
Albuquerque, New Mexico
The purpose of this clinical trial is to investigate the effects of multiple sessions of transcranial direct current stimulation (tDCS) delivered while participants complete tasks that target social learning with high functioning adults with ASD and/or high traits of ASD.
The main question it aims to answer is:
What are the effects of multiple sessions of active compared to sham tDCS, with tDCS simultaneously paired with social learning tasks, from employing a within-subject, cross-over randomized controlled trial design?
Participants will:
* Complete a randomly assigned block of 5 sessions of active and a block of 5 sessions of sham tDCS, with a four-week break occurring between the two blocks.
* Complete social learning tasks simultaneously during receipt of tDCS at each session (whether receiving active or sham tDCS).
* Complete behavioral, physiological, and electrophysiological testing before and after each block of active or sham tDCS.
* Complete a social validity questionnaire after completion of the study.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 35
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Pregnancy, Hospitalization, Others
20 Participants Needed
Telehealth vs In-Person Behavior Therapy for Autism
Alamogordo, New Mexico
The purpose of the research is to determine whether parent-mediated behavior therapy for challenging behavior commonly displayed by children with autism spectrum disorder (ASD) can be as effective when delivered via telehealth as when delivered in-person.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:2 - 7
Key Eligibility Criteria
Disqualifiers:Severe Behavior, Sensory Impairment, Genetic Condition, Others
90 Participants Needed
Lumateperone for Irritability in Autism
Colorado Springs, Colorado
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Fragile X, Others
Must Be Taking:ADHD Medications
174 Participants Needed
Lumateperone for Schizophrenia and Bipolar Disorder
Colorado Springs, Colorado
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Suicidal Risk, Catatonia, Psychotic Features, Others
Must Be Taking:Psychostimulants
500 Participants Needed
Diné Parents Taking Action for Autism
Flagstaff, Arizona
The goal of this clinical trial is to learn if a family support program helps Navajo parents and guardians of children with autism spectrum disorder (ASD) or other developmental concerns. The main questions it aims to answer are:
* Is the program something families find useful and easy to take part in?
* Does the program raise parents' knowledge and confidence in using strategies that support their child's development?
* Does the program help children improve in areas such as social communication?
Researchers will compare two groups:
* One group of parents will join the program right away.
* The other group will join the program after waiting.
Participants will:
* Be randomly placed into the "immediate" or "waitlist control" group using simple randomization.
* Take part in sessions led by trained Navajo Family Advisors, who are parents of children with ASD.
* Learn and practice strategies they can use at home to support their child
* Answer surveys about their experience, knowledge, and their child's progress
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Non-Navajo, Child Age 13+, Others
29 Participants Needed
This pilot study will test whether combining L-theanine and paraxanthine improves sustained attention, inhibitory control, and overall cognition in adults with ADHD and ASD. Two parallel randomized, single-blinded, repeated-measures crossover trials will be conducted. Participants will complete neuropsychological testing, fMRI scanning, and self-report measures following administration of the L-theanine-paraxanthine combination compared to placebo.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Sex:Male
Key Eligibility Criteria
Disqualifiers:Visual, Auditory, Neurological, Psychiatric, Others
Must Be Taking:Stimulants
24 Participants Needed
This trial tests a treatment called Microbiota Transfer Therapy (MTT) for children with Autism Spectrum Disorder and gut problems. It uses antibiotics to clear bad bacteria, cleans the bowel, and then adds good bacteria from donor stool over a few months. The goal is to see if this helps improve their symptoms. Microbiota Transfer Therapy (MTT) has shown significant improvements in gastrointestinal and autism symptoms in previous studies, with benefits persisting for some time after treatment.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Single-gene Disorders, Major Brain Malformation, Others
Must Not Be Taking:Antibiotics, Probiotics, Psychotropics, Others
50 Participants Needed
Mindfulness Training for Autism
Tempe, Arizona
The purpose of this study to measure brain functioning before and after stress-reduction classes to better understand how symptom improvements relate to brain functioning in adults with ASD (Autism Spectrum Disorder). Participants will be randomly assigned to one of two stress reduction classes that will meet once a week for 8 weeks. One group will complete a structured training program called Mindfulness Based Stress Reduction (MBSR) that involves teaching about increased mindfulness strategies and gentle stretching. The other group will review relaxation techniques and other stress reduction strategies and will include social support. Structural and functional MRI, EEG, and behavioral self-report data will be collected to understand more about how the brain changes in subtle ways when people feel better and are more aware of their emotional state.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
108 Participants Needed
The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Autism-spectrum disorder with Gastrointestinal disorders (constipation, diarrhea, and/or abdominal pain). MTT involves a combination of 14 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by 1 day of bowel cleanse using Miralax, followed by 5 days of high dose MTP-101P with an antacid, followed by 12 weeks of a lower maintenance dose of MTP-101P with an antacid.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:4 - 18
Key Eligibility Criteria
Disqualifiers:Single-gene Disorder, Major Brain Malformation, Severe GI Problems, Others
Must Not Be Taking:Antibiotics, Probiotics, Psychotropics, Others
60 Participants Needed
ML-004 for Autism Spectrum Disorder
Phoenix, Arizona
This trial is testing a treatment called ML-004 to see if it can help improve social communication skills in adolescents and adults with Autism Spectrum Disorder (ASD). The study will involve about 150 participants to determine its effectiveness.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 45
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others
150 Participants Needed
Leucovorin for Autism
Phoenix, Arizona
This trial tests a liquid form of leucovorin calcium in young children with autism spectrum disorder (ASD) to see if it improves their social communication and behavior. The study focuses on children who have significant social and communication challenges. The treatment aims to enhance brain function, potentially leading to better communication and interaction skills.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:30 - 60
Key Eligibility Criteria
Disqualifiers:Epilepsy, Genetic Syndromes, Liver Disease, Others
Must Not Be Taking:Chemotherapy, Antimalarial, Immunosuppressive, Antibiotics
80 Participants Needed
Levoleucovorin Calcium for Autism
Phoenix, Arizona
This trial is testing a liquid form of leucovorin calcium to see if it can help young children with autism improve their language skills and behavior. The study involves young children who have autism and language delays. The treatment aims to enhance brain function and development. Leucovorin calcium has shown potential benefits in improving verbal communication and behavior in children with autism spectrum disorder (ASD) who test positive for cerebral folate receptor autoantibodies.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:30 - 60
Key Eligibility Criteria
Disqualifiers:Epilepsy, Genetic Syndromes, Liver Disease, Others
Must Not Be Taking:Chemotherapy, Antimalarial, Immunosuppressive, Antibiotics
80 Participants Needed
Folinic Acid for Language Impairment in Autism Spectrum Disorder
Phoenix, Arizona
This trial is testing folinic acid, a vitamin, to see if it can help children with autism who have language problems. The study focuses on whether this vitamin can improve brain function and language skills. Children with moderate language issues will participate. Folinic acid has been studied for its potential to improve verbal communication in children with autism and language impairment.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Major Depression, Bipolar, Psychotic Disorder, Others
Must Not Be Taking:Anticonvulsants, Bactrim, Valproic Acid
56 Participants Needed
Pimavanserin for Autism Spectrum Disorder
Centennial, Colorado
This trial is testing pimavanserin, a medication that may help reduce irritability in children and teenagers with autism. The study focuses on kids aged 5 to 17 who have this symptom. Pimavanserin works by balancing brain chemicals to help them feel calmer. The goal is to see if the medication is safe and effective over time.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:5 - 18
Key Eligibility Criteria
Disqualifiers:Not Listed
209 Participants Needed
Marijuana-based Drug for Anxiety in Autism
Phoenix, Arizona
The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are:
Will a marijuana-based drug help anxiety in autistic adults?
Anxiety can make socializing and working more difficult for people. Researchers will compare a marijuana based drug (that is mostly CBD with a small amount of THC) to a placebo (a look-alike substance that contains no drug) to see if the drug makes symptoms of anxiety better.
Participants will take the drug (or a placebo) every day for 8 weeks and keep a diary to record the time they took the drug, and their feelings each day. The drug is taken orally in drops once or twice a day. The study staff will speak to the participants weekly either over the phone or in the clinic. Clinic visits once every 2 weeks for checkups and tests. The researchers will make sure participants are healthy and see if there are any changes in anxiety.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 45
Key Eligibility Criteria
Disqualifiers:Psychotic Disorder, Substance Use, Others
Must Not Be Taking:Opiates, Methamphetamine, Cocaine, Others
108 Participants Needed
Photobiomodulation for Autism
Phoenix, Arizona
For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical practice of treating autism. At the beginning, at five weeks, and at the end of study, the clinician will complete the CARS-2, SRS, CGI, and a caregiver interview; additionally, questionnaires will be administered to caregivers during one of the 1-hour weekly treatment sessions.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:4 - 12
Key Eligibility Criteria
Disqualifiers:Self-abusive Behavior, GERD, Genetic Syndromes, Others
Must Not Be Taking:Stimulants, Antipsychotics, Antihistamines
30 Participants Needed
ML-004 for Autism
Phoenix, Arizona
This trial is testing the safety of a treatment called ML-004 in adolescents and adults with Autism Spectrum Disorder (ASD). The main goal is to ensure that the treatment does not cause any harmful side effects.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:12 - 46
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others
120 Participants Needed
Therapeutic Horseback Riding for Autism Spectrum Disorder
Aurora, Colorado
This randomized control trial (RCT) seeks to assess the mechanisms underlying Therapeutic Horseback Riding's (THR) previously observed significant positive effects on ASD youth, particularly those with co-occurring psychiatric disorders, and to refine information on the durability, dose and sub-population effects of the intervention.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:6 - 17
Key Eligibility Criteria
Disqualifiers:Not Listed
250 Participants Needed
TB006 for Autism
Phoenix, Arizona
Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 35
Key Eligibility Criteria
Disqualifiers:Epilepsy, Liver Disease, Kidney Disease, Others
45 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
Mindfulness Intervention for Autism Spectrum Disorder
Phoenix, Arizona
Adolescents with ASD often have co-occurring mental health symptoms like stress, anxiety, and depression. The investigators are conducting this research study to develop interventions for adolescents with ASD that will improve co-occurring mental health symptoms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:13 - 18
Key Eligibility Criteria
Disqualifiers:Non-verbal, IQ <70, Physical Disability, Others
28 Participants Needed
CBD for Autism
Aurora, Colorado
This is a randomized, placebo-controlled study but all study participants will receive the active study medication at some point during the study for at least 12 weeks, and some children with receive CBD for the entire study.
Trial Details
Trial Status:Active Not Recruiting
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Not Listed
86 Participants Needed
Executive Functioning Interventions for Autism
Aurora, Colorado
This project aims to follow up on a prior project examining the impact of training therapists in an executive functioning intervention Unstuck and On Target (UOT) adapted for community mental health settings. Study aims are to test the clinical and implementation effectiveness of training mental health therapists in Unstuck and On Target, an executive functioning intervention, relative to Unified Protocol for Children, a transdiagnostic intervention for emotional disorders. This includes examining the implementation of Unstuck and associated outcomes (e.g., effective delivery, expanded use of Unstuck beyond autism, the feasibility of Unstuck) and impact on changes in child executive functioning and behaviors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 99
Key Eligibility Criteria
Disqualifiers:Autism, Others
672 Participants Needed
School-Based Interventions for Anxiety in Autism
Aurora, Colorado
The goal of this clinical trial is to compare two school based interventions to manage anxiety in autistic students. The main question\[s\] it aims to answer are: 1) Compare the effectiveness of Facing Your Fears-School Based Program (FYF-SB) with Zones of Regulation (ZOR) on anxiety reduction and emotion regulation; and 2) examine the feasibility and satisfaction of FYF-SB and ZOR, according to students, caregivers and school providers. Autistic students with anxiety between 8-14 years will be randomized to either FYF-SB and ZOR. They will participate in one of the programs for 12 weeks and pre, post and follow-up measures will occur.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 15
Key Eligibility Criteria
Disqualifiers:Intellectual Disability, Significant Behavior Challenge, Others
200 Participants Needed
Horse-Centered Occupational Therapy for Autism
Denver, Colorado
The goal of this clinical trial is to learn about occupational therapy integrating horses for autistic youth. The main questions it aims to answer are:
* Does occupational therapy integrating horses improve self-regulation in autistic youth
* Does occupational therapy integrating horses affect salivary cortisol and alpha-amylase
Participants will receive 10 weeks of occupational therapy, and will be asked to provide saliva samples each week.
Researchers will compare occupational therapy integrating horses to occupational therapy in a clinic to see if integrating horses affects self-regulation.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:6 - 11
Key Eligibility Criteria
Disqualifiers:Smoking, Horseback Riding, Animal Abuse, Others
Must Not Be Taking:Steroids
73 Participants Needed
Facing Your Fears Therapy for ASD with Intellectual Disability
Aurora, Colorado
This trial tests a program called 'Facing Your Fears' for teenagers with autism and intellectual disabilities. It aims to help them manage anxiety by teaching coping skills. The 'Facing Your Fears' program has been previously adapted and tested for adolescents with high-functioning autism spectrum disorders and anxiety, showing encouraging initial results.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:12 - 18
Key Eligibility Criteria
Disqualifiers:Thought Disorder, High Irritability, Attendance Issues
73 Participants Needed
Tasimelteon for Autism and Sleep Disorders
Boulder, Colorado
This trial is testing a daily pill called tasimelteon to help children and adults with Autism Spectrum Disorder (ASD) who have trouble sleeping. The medication aims to improve sleep by helping to regulate the body's internal clock.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 65
Key Eligibility Criteria
Disqualifiers:Impaired Liver Function, Pregnancy, Others
Must Not Be Taking:Sedatives, Stimulants
100 Participants Needed
Virtual Trauma Support for Autistic Adults with PTSD
Laramie, Wyoming
The goal of this single-group clinical trial is to learn about the initial efficacy and feasibility of telehealth-delivered Written Exposure Therapy (WET) for autistic adults with traumatic stress symptoms. The main questions the investigators aim to answer are:
* Do symptoms of posttraumatic stress disorder (PTSD) and co-occurring mental health concerns decrease after receiving WET?
* Do biobehavioral health outcomes, including objective (Fitbit indicators of activity, sleep, and heart rate) and subjectively-reported health variables (e.g., sleep, pain, health-related quality of life), improve after receiving WET?
* How do autistic adults experience WET, and how can this program be modified and enhance in the future in collaboration with autistic adults?
Participants will complete the following as part of the study, which is completed entirely over telehealth.
* Participants will first complete an initial assessment, involving brief measures of cognition and autistic traits, as well as interviews and questionnaires about PTSD, mental health, and physical health. If eligible, participants will proceed to the following steps:
* Eligible participants will then start wearing a Fitbit, to be used for the duration of the study.
* Participants will then participate in 5 weekly virtual visits involving the WET protocol, including weekly brief assessment of PTSD and mental and physical health.
* Then, participants will complete a sixth virtual visit the following week where PTSD, mental and physical health, and treatment feedback are assessed.
* Lastly, participants will complete virtual visits 1 and 6 months later involving re-assessment of PTSD and mental and physical health.
Therefore, this is a pre-post single group design, where all participants will receive WET to establish initial efficacy and feasibility. Investigators will also consult with an autistic advisory board throughout the project, and make adaptations as recommended in consultation with autistic adults. The goal is to better understand the initial efficacy and feasibility of WET for supporting autistic adults who have experienced trauma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Not Listed
30 Participants Needed
ARD-501 for Autism
Las Vegas, Nevada
This trial tests a new medication called ARD-501 for safety and effectiveness in people with Autism Spectrum Disorder (ASD). Participants will receive the medication in two different doses to compare results. The goal is to see if ARD-501 can help improve symptoms of ASD.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:17 - 30
Key Eligibility Criteria
Disqualifiers:Seizure Disorder, Major Depressive Disorder, Others
Must Not Be Taking:Benzodiazepines, Cannabinoids, Opioids, Others
12 Participants Needed
Educational Program for Suicide Prevention in Autism
Salt Lake City, Utah
The goal of this study is to pilot test a new educational intervention for organization members focused on suicide prevention for autistic people. The main questions it aims to answer are:
* Does participating in the intervention increase participants' knowledge, skills, and actions to support suicide prevention for autistic people?
* What feedback do participants have to help improve the intervention?
Participants will:
* engage in a four-part virtual educational intervention
* answer questions via online survey before, after, and 3-months after the intervention
* participate in an optional interview to provide feedback
No Placebo Group
Trial Details
Trial Status:Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
30 Participants Needed
Know someone looking for new options?
Spread the word